Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance …

Introduction Metastatic spread to the brain is common in patients with non–small cell lung
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials …

Introduction Afatinib is an effective first-line treatment in patients with epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in …

Purpose Several cases have been reported in which central nervous system (CNS)
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …

Introduction Epidermal growth factor receptor (EGFR) mutation T790M accounts for
approximately half of acquired resistances to EGFR-tyrosine kinase inhibitor (TKI). Because …

BACKGROUND The secondary epidermal growth factor receptor (EGFR) mutation
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …

Brain metastases are a common and devastating consequence of disease progression in
patients with non–small cell lung cancer (NSCLC). The epidermal growth factor receptor …

Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …

Background: Osimertinib demonstrated promising efficacy for refractory leptomeningeal
metastases (LM) in preclinical data and a clinical study at 160 mg, but there is limited data …